Our findings unveil a novel epigenetic strategy employed by PRV to evade host antiviral responses and highlight JMJD6 as a potential therapeutic target for combating herpesvirus infections.IMPORTANCEThe ongoing conflict between viruses and host antiviral defenses is central to viral pathogenesis. This evidence concerns the gene JMJD6 and Herpesviridae infectious disease.